Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe LIBRETTO-431 page now shows a 403 Forbidden error, replacing the previous study details and removing associated documents, effectively blocking access to the trial's information.SummaryDifference19%

- Check9 days agoChange DetectedThe page underwent a revision bump from v3.6.6 to v3.7.0, indicating a platform/template upgrade for the ClinicalTrials.gov page. This update does not modify the study details or displayed data.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, indicating a minor update to the record. This change does not modify the study text or data presented on the page.SummaryDifference0.0%

- Check30 days agoChange DetectedA funding note '2019 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, indicating NIH support for the LIBRETTO-431 trial. This broadens the funding attribution in the study record.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision: v3.6.5 was applied, replacing the previous v3.6.4, indicating a backend or documentation update with no visible changes to the study content.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, representing a platform software upgrade. No study content, terminology, or essential page functionality appears to be altered by this change.SummaryDifference0.0%

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.